33 results
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
12 Dec 23
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
6:10am
-201-689-8560 (international) and use conference ID 13743026. To access the webcast presentation, please click here.
A replay of the webcast
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
”, with respect to a Party, shall mean the possession of such Party of the ability to grant a license, sublicense, a right to access, a right to use, or other … by the Applicable Laws, reasonable access to all Product Data and results, generated or obtained by or on behalf of and Controlled by Licensee or its
6-K
EX-99.2
CNTB
Connect Biopharma Holdings Ltd
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
(international) and use conference ID 13742753. To access the webcast presentation, please click here.
A replay of the webcast and accompanying
6-K
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
have been prepared with the presumption that users of the unaudited interim condensed consolidated financial statements have read or have access
6-K
89roznpoj6otf6 fa
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
F-3/A
n8akuo0ad0zhtx0
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm
F-3/A
uyi ypcu8
20 May 22
Shelf registration (foreign) (amended)
6:54pm
F-3
l5qc2jyho4 n7pdw
15 Apr 22
Shelf registration (foreign)
5:27pm
F-3
EX-1.2
aa5qy4ceo97x7o4
15 Apr 22
Shelf registration (foreign)
5:27pm
20-F
9bbsed4tqw36
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-1.1
yqt5yu
31 Mar 22
Annual report (foreign)
4:33pm
20-F
EX-4.13
eg8eicp x4c
31 Mar 22
Annual report (foreign)
4:33pm
6-K
EX-99.1
vwiims5gxa1p3 vp
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
424B4
7m7fx2qa
19 Mar 21
Prospectus supplement with pricing info
4:49pm
F-1/A
t6ro289 3q10e2y
18 Mar 21
Registration statement (foreign) (amended)
6:15am
F-1/A
EX-10.2
144f25s cme
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
F-1/A
4ncyd
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
F-1/A
EX-99.1
bvvqb dhc3sdk3
12 Mar 21
Registration statement (foreign) (amended)
5:02pm